Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

APCIO 2019 to showcase, network the region’s interventional oncology fraternity

Pank Jit Sin
13 Aug 2019
Dr Alex Tang, organizing chairman of APCIO 2019

Kuala Lumpur will play host to the 6th Asia-Pacific Congress of Interventional Oncology 2019 (APCIO 2019) on 2–5 October. Interventional Oncology (IO) is a minimally invasive subspecialty offering various advanced and state-of-art services in the management of oncological disorders. IO is recognized as the fourth pillar in oncology and it has undergone tremendous technological growth in the last two decades. Numerous minimally invasive procedures are available in this subspecialty, offering another dimension of advanced cancer care.

Themed ‘Interventional Therapy in Modern Oncology: Technological Integration Beyond Boundaries,’ it will be held in conjunction with the 2nd Multidisciplinary Oncology Symposium Malaysia and the Malaysian Society of Interventional Radiology Annual Scientific Meeting (MYSIR ASM). MIMS Doctor spoke to Dr Alex Tang, organizing chairman of APCIO 2019, to get some information and his thoughts on the upcoming conference. 

A meeting of eminent interventional oncologists
Although the majority of participants will hail from the Asia-Pacific region, the conference will also see participation from an international audience, including those from the US and Europe. In total, Tang expects close to 1,000 participants to sign up for the congress.

Tang said the congress’ approach is one which is multidisciplinary in nature with six subspecialties sharing the limelight. There will be intersociety collaborations with associations such as the Society of Interventional Radiology (SIR USA), US Society of Interventional Oncology (SIO), Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Asia-Pacific Association of Image-Guided Minimally Invasive Therapy in Oncology (APAITO), Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR), Asia-Pacific Primary Liver Cancer Expert (APPLE) Association, Asian Pacific Association for the Study of the Liver (APASL) and Malaysian Oncological Society (MOS). 

In his welcoming address, Tang said that the best way to manage each patient is through a multidisciplinary team (MDT) approach, which incorporates the latest technologies, accurate diagnosis and appropriate treatment. Thus, the conference will feature MDT tracks for the liver cancer, lung cancers, colorectal cancers, etc. Various tracks for the nurses, radiographers and technicians are also included. Perhaps most importantly, Tang stressed on an empathetic and humanistic approach to patient care.

Tang hopes the congress will serve to be a congregation point for delegates to form new networks and strengthen existing bonds among the local and international fraternity.   

A real reward for young investigators
One of the important highlights of the conference will be the young investigator award. While there will be more than 80 awards given out to the participants, Tang and committee has gone the extra mile to provide a memorable prize for the first and second place winners.

Tang said: “The first prize winner will get to train under Professor Shinichi Hori, of Osaka University, while the second place winner will get to intern with Professor Toshihiro Tanaka, of Nara Medical University, Japan.” These two professors are well known for their research work and an attachment with their research facilities without any referral is next to impossible.

To add to the prestige of the awards, Tang said the third and fourth place winners will be invited to present their paper at the Society of Interventional Radiology’s conference in Seattle, US, in March next year. Tang said he wanted the winners to have a truly memorable experience instead of run-of-the-mill cash or trophy prizes.

Visions of APCIO

APCIO aims to establish a platform of training of the young bloods for the next generation as well as a biennial academic forum for sharing and updates in this rapidly evolving interventional oncology field. In addition, efforts are being taken to the standardize and enhance regional practices in IO among the Asian countries.

The congress will be held in KLCC, our iconic venue and pride of the country. in transcending the world through the academic congresses. Further information about the congress and registration procedures can be found at: apcio2019.com/index.php


Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.